Yield10 Bioscience Stock Alpha and Beta Analysis
| YTEN Stock | USD 0.01 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Yield10 Bioscience. It also helps investors analyze the systematic and unsystematic risks associated with investing in Yield10 Bioscience over a specified time horizon. Remember, high Yield10 Bioscience's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Yield10 Bioscience's market risk premium analysis include:
Beta 6.68 | Alpha 10.46 | Risk 98.94 | Sharpe Ratio 0.12 | Expected Return 11.84 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Yield10 |
Yield10 Bioscience Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Yield10 Bioscience market risk premium is the additional return an investor will receive from holding Yield10 Bioscience long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Yield10 Bioscience. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Yield10 Bioscience's performance over market.| α | 10.46 | β | 6.68 |
Yield10 Bioscience Fundamentals Vs Peers
Comparing Yield10 Bioscience's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Yield10 Bioscience's direct or indirect competition across all of the common fundamentals between Yield10 Bioscience and the related equities. This way, we can detect undervalued stocks with similar characteristics as Yield10 Bioscience or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Yield10 Bioscience's fundamental indicators could also be used in its relative valuation, which is a method of valuing Yield10 Bioscience by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Yield10 Bioscience to competition |
| Fundamentals | Yield10 Bioscience | Peer Average |
| Return On Equity | -15.08 | -0.31 |
| Return On Asset | -1.78 | -0.14 |
| Operating Margin | (7.12) % | (5.51) % |
| Current Valuation | 2.07 M | 16.62 B |
| Shares Outstanding | 692.68 K | 571.82 M |
| Shares Owned By Insiders | 17.54 % | 10.09 % |
| Shares Owned By Institutions | 0.03 % | 39.21 % |
Yield10 Bioscience Opportunities
Yield10 Bioscience Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 10670 shares by Schuler Jack W of Yield10 Bioscience at 0.3014 subject to Rule 16b-3 | 02/21/2025 |
About Yield10 Bioscience Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Yield10 or other stocks. Alpha measures the amount that position in Yield10 Bioscience has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 0.22 | 0.2 | Price To Sales Ratio | 36.43 | 34.6 |
Yield10 Bioscience Upcoming Company Events
As portrayed in its financial statements, the presentation of Yield10 Bioscience's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Yield10 Bioscience's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Yield10 Bioscience's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Yield10 Bioscience. Please utilize our Beneish M Score to check the likelihood of Yield10 Bioscience's management manipulating its earnings.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Yield10 Bioscience
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Yield10 Bioscience technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.